about
Nephrotic-range proteinuria on interferon-β treatment: immune-induced glomerulonephritis or other pathway?Overlap between dermatomyositis and ANCA vasculitides.Pathogenesis of glomerular haematuria.Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis.Haematuria on the Spanish Registry of Glomerulonephritis.CD163-Macrophages Are Involved in Rhabdomyolysis-Induced Kidney Injury and May Be Detected by MRI with Targeted Gold-Coated Iron Oxide Nanoparticles.Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: A review.The effect of some medications given to CKD patients on vitamin D levels.Is High-Volume Online Hemodiafiltration Associated With Malnutrition?Adverse effects of the renal accumulation of haem proteins. Novel therapeutic approaches.Remission of Hematuria Improves Renal Survival in IgA Nephropathy.Gastrointestinal complications induced by sevelamer crystals.Podocytes are new cellular targets of haemoglobin-mediated renal damage.Assessment of nutritional status in haemodialysis patients.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?Daily Home Hemodialysis Is an Available Option for Renal Replacement Therapy in Spain.[Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease][Vitamin D deficiency in a Spanish cohort of patients with chronic kidney disease]Factors related with the progression of chronic kidney disease[Metabolic syndrome is associated with cardiovascular events in haemodialysis]Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysisHeyde syndrome: Correction of anemia after aortic valve replacement in a hemodialysis patientIgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated?
P50
Q35227661-67000BEA-2DF7-46D7-B30E-3F043FF17399Q35310775-9A39DD79-7709-4615-A434-3C0772AB9037Q35567846-F9585E5A-BE33-41C4-832E-2F32B17C0ECFQ36359848-7A3E3820-A7BC-4D1E-B142-FFFD469834E7Q36511959-6E7BB75A-A8BE-4D38-AC35-441CAC03BC24Q36882988-F09B48E9-919D-4628-841B-3E749A1D50DFQ38484336-C18AA11F-13E3-4876-82C9-4C1AD98532A2Q38572321-84262F88-8392-40D1-A16C-1E603CCDDF36Q38611698-74582602-351B-4C1B-980B-F00F3B236450Q39408572-4BA2661E-A71C-4840-9335-7BA70746FAFAQ40168439-DFF438E8-DBA3-4ACD-A271-DB8894E72DAEQ41510628-8A3B7D98-3994-453E-A3CA-637606D1C211Q47330519-C57E797A-07A6-4271-9539-C6D5465379B3Q51260948-286E5A39-B838-4061-B34A-C8A87A49FCC0Q51451952-B4320D5D-04E7-469B-B693-D4E3307FF3CEQ53563573-0BAB692F-FF21-416A-B45A-5EA3C31FCD52Q53792673-BFF8B2F5-0713-4E98-8FD1-ADCF708ED122Q84635338-6213800F-8FDC-4EF0-B360-CC0DAD89B58FQ85535551-FDF66A72-DDDA-4951-A266-3D0B1AE621C9Q86437302-82F21498-2E59-4B34-BD78-242CF21FD75DQ87165243-5AADCE59-39A9-4382-BE26-6FBB403CED7BQ87916341-0597B00E-A20C-4949-B060-F1FA6B145A51Q88012591-76A1029B-1D2D-4FC8-A73A-2D203CF2AA29Q88321546-4C77DB01-FF1A-4ABA-972A-A799D1407623
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claudia Yuste
@ast
Claudia Yuste
@en
Claudia Yuste
@es
Claudia Yuste
@nl
type
label
Claudia Yuste
@ast
Claudia Yuste
@en
Claudia Yuste
@es
Claudia Yuste
@nl
prefLabel
Claudia Yuste
@ast
Claudia Yuste
@en
Claudia Yuste
@es
Claudia Yuste
@nl
P108
P106
P108
P21
P31
P496
0000-0001-6327-9588